Original articleTaiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities
Keywords
Cited by (0)
Conflicts of interest: Dr Chia-Yu Chu received consulting fees, travel support, and payment for lectures from Boehringer Ingelheim International GmbH and honoraria from AstraZeneca and Roche. Dr Kuan-Yu Chen received travel support from Boehringer Ingelheim and MSD, and payment for lectures from AstraZeneca, Roche, Eli Lilly, Boehringer Ingelheim, MSD, Bristol–Myers Squibb, SANOFI. Dr Chih-Hung Lee has conducted clinical trials for Janssen-Cilag Pharmaceutical, Novartis Pharmaceutical, and Roche Pharma; served as a consultant or received speaker fee, consulting fee, or travel support from AbbVie Inc., Janssen-Cliag Pharmaceutical, Pfizer Pharmaceutical, and Novartis Pharmaceutical. Drs John Wen-Cheng Chang, Yu-Feng Wei, Wei-Ming Wang declares no conflict of interest regarding this manuscript.